Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TGFBR2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TGFBR2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TGFBR2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TGFBR2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TGFBR2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TGFBR2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TGFBR2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048660 | Colorectum | MSS | regulation of smooth muscle cell proliferation | 48/3467 | 180/18723 | 4.32e-03 | 3.07e-02 | 48 |
GO:00016662 | Colorectum | MSS | response to hypoxia | 75/3467 | 307/18723 | 5.56e-03 | 3.78e-02 | 75 |
GO:00485681 | Colorectum | MSS | embryonic organ development | 100/3467 | 427/18723 | 6.00e-03 | 4.03e-02 | 100 |
GO:0048661 | Colorectum | MSS | positive regulation of smooth muscle cell proliferation | 30/3467 | 104/18723 | 6.69e-03 | 4.38e-02 | 30 |
GO:20003772 | Colorectum | MSS | regulation of reactive oxygen species metabolic process | 42/3467 | 157/18723 | 6.83e-03 | 4.40e-02 | 42 |
GO:0031099 | Colorectum | MSS | regeneration | 51/3467 | 198/18723 | 6.99e-03 | 4.49e-02 | 51 |
GO:0048762 | Colorectum | MSS | mesenchymal cell differentiation | 59/3467 | 236/18723 | 7.79e-03 | 4.84e-02 | 59 |
GO:0010463 | Colorectum | MSS | mesenchymal cell proliferation | 14/3467 | 39/18723 | 7.79e-03 | 4.84e-02 | 14 |
GO:00160493 | Colorectum | FAP | cell growth | 112/2622 | 482/18723 | 2.40e-08 | 2.30e-06 | 112 |
GO:00487324 | Colorectum | FAP | gland development | 103/2622 | 436/18723 | 3.61e-08 | 3.12e-06 | 103 |
GO:00420604 | Colorectum | FAP | wound healing | 99/2622 | 422/18723 | 9.50e-08 | 6.33e-06 | 99 |
GO:00459273 | Colorectum | FAP | positive regulation of growth | 66/2622 | 259/18723 | 6.11e-07 | 3.05e-05 | 66 |
GO:00485454 | Colorectum | FAP | response to steroid hormone | 81/2622 | 339/18723 | 6.22e-07 | 3.08e-05 | 81 |
GO:00068982 | Colorectum | FAP | receptor-mediated endocytosis | 62/2622 | 244/18723 | 1.47e-06 | 6.39e-05 | 62 |
GO:00097434 | Colorectum | FAP | response to carbohydrate | 63/2622 | 253/18723 | 2.52e-06 | 9.77e-05 | 63 |
GO:00715591 | Colorectum | FAP | response to transforming growth factor beta | 63/2622 | 256/18723 | 3.82e-06 | 1.32e-04 | 63 |
GO:00071782 | Colorectum | FAP | transmembrane receptor protein serine/threonine kinase signaling pathway | 81/2622 | 355/18723 | 4.28e-06 | 1.46e-04 | 81 |
GO:00486392 | Colorectum | FAP | positive regulation of developmental growth | 47/2622 | 174/18723 | 4.55e-06 | 1.52e-04 | 47 |
GO:00605602 | Colorectum | FAP | developmental growth involved in morphogenesis | 58/2622 | 234/18723 | 7.21e-06 | 2.19e-04 | 58 |
GO:00715601 | Colorectum | FAP | cellular response to transforming growth factor beta stimulus | 61/2622 | 250/18723 | 7.22e-06 | 2.19e-04 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TGFBR2 | SNV | Missense_Mutation | | c.1528G>A | p.Glu510Lys | p.E510K | P37173 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
TGFBR2 | SNV | Missense_Mutation | | c.382G>A | p.Asp128Asn | p.D128N | P37173 | protein_coding | tolerated(0.83) | benign(0.061) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
TGFBR2 | SNV | Missense_Mutation | novel | c.673A>G | p.Thr225Ala | p.T225A | P37173 | protein_coding | tolerated(0.89) | benign(0) | TCGA-LL-A50Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
TGFBR2 | SNV | Missense_Mutation | | c.1559N>A | p.Arg520Gln | p.R520Q | P37173 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
TGFBR2 | insertion | Nonsense_Mutation | novel | c.939_940insTTGCAGTGAGCAGAGATCGTGCCATTGCACTGCTGCCTGGGTA | p.Thr314LeufsTer3 | p.T314Lfs*3 | P37173 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TGFBR2 | SNV | Missense_Mutation | novel | c.116A>C | p.Lys39Thr | p.K39T | P37173 | protein_coding | tolerated_low_confidence(0.15) | benign(0.026) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | rs886039551 | c.1411N>A | p.Asp471Asn | p.D471N | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | | c.1664N>T | p.Thr555Ile | p.T555I | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TGFBR2 | SNV | Missense_Mutation | | c.1393G>A | p.Glu465Lys | p.E465K | P37173 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | rs104893809 | c.1684C>T | p.Arg562Cys | p.R562C | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | agonist | 178101755 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | TGF-BR2 mab | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | TG-C | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565755 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565835 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | agonist | 348353672 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | irinotecan | IRINOTECAN | 27160286 |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565874 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 223366128 | GALUNISERTIB | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565800 | | |